Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
4
Regulatory Approvals
No patent data available. Pre-approval drugs may not have Orange Book listings.
Altuvoct
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Altuvoct can be used for all age groups.
Iblias
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).Iblias can be used for all age groups.
View on EMAHelixate NexGen
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor-VIII deficiency). This preparation does not contain von Willebrand factor and is therefore not indicated in von Willebrand's disease.
View on EMAKogenate Bayer
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor-VIII deficiency). This preparation does not contain von Willebrand factor and is therefore not indicated in von Willebrand's disease.
View on EMA